349 related articles for article (PubMed ID: 11920478)
1. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia.
Kalir T; Wang BY; Goldfischer M; Haber RS; Reder I; Demopoulos R; Cohen CJ; Burstein DE
Cancer; 2002 Feb; 94(4):1078-82. PubMed ID: 11920478
[TBL] [Abstract][Full Text] [Related]
2. Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
Shibata K; Kajiyama H; Mizokami Y; Ino K; Nomura S; Mizutani S; Terauchi M; Kikkawa F
Gynecol Oncol; 2005 Jul; 98(1):11-8. PubMed ID: 15907336
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical staining of GLUT1 in benign, hyperplastic, and malignant endometrial epithelia.
Wang BY; Kalir T; Sabo E; Sherman DE; Cohen C; Burstein DE
Cancer; 2000 Jun; 88(12):2774-81. PubMed ID: 10870060
[TBL] [Abstract][Full Text] [Related]
4. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor.
Cai Y; Zhai JJ; Feng BB; Duan XZ; He XJ
J Obstet Gynaecol Res; 2014 Jul; 40(7):1925-30. PubMed ID: 25056472
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical detection of glucose transporter GLUT1 in benign and malignant fallopian tube epithelia, with comparison to ovarian carcinomas.
Kalir T; Rahaman J; Hagopian G; Demopoulos R; Cohen C; Burstein DE
Arch Pathol Lab Med; 2005 May; 129(5):651-4. PubMed ID: 15859637
[TBL] [Abstract][Full Text] [Related]
6. Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign and malignant ovarian endometriotic cysts.
Nezhat F; Cohen C; Rahaman J; Gretz H; Cole P; Kalir T
Cancer; 2002 Jun; 94(11):2935-40. PubMed ID: 12115382
[TBL] [Abstract][Full Text] [Related]
7. Clinical factors and biomarkers in ovarian tumors development.
Vrabie CD; Petrescu A; Waller M; Dina I
Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
[TBL] [Abstract][Full Text] [Related]
8. Expression of GLUT-1 glucose transporter in borderline and malignant epithelial tumors of the ovary.
Cantuaria G; Magalhaes A; Penalver M; Angioli R; Braunschweiger P; Gomez-Marin O; Kanhoush R; Gomez-Fernandez C; Nadji M
Gynecol Oncol; 2000 Oct; 79(1):33-7. PubMed ID: 11006027
[TBL] [Abstract][Full Text] [Related]
9. [Expression of glucose transporter-1 and its correlation with basic fibroblast growth factor and proliferating cell nuclear antigen in epithelial ovarian neoplasm].
Zhao SJ; Liu JY; Ren FR; Feng YJ
Zhonghua Fu Chan Ke Za Zhi; 2005 Apr; 40(4):264-8. PubMed ID: 15924676
[TBL] [Abstract][Full Text] [Related]
10. B7-H4 overexpression in ovarian tumors.
Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
[TBL] [Abstract][Full Text] [Related]
11. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
12. u-PA expression in benign, borderline and malignant ovarian tumors.
Kiziridou AD; Toliou T; Stefanou D; Agnantis N
Anticancer Res; 2002; 22(2A):985-90. PubMed ID: 12014682
[TBL] [Abstract][Full Text] [Related]
13. Metallothionein expression and nuclear size in benign, borderline, and malignant serous ovarian tumours.
Tan Y; Sinniah R; Bay BH; Singh G
J Pathol; 1999 Sep; 189(1):60-5. PubMed ID: 10451489
[TBL] [Abstract][Full Text] [Related]
14. Fascin expression in serous tumors of ovary correlates with aggressiveness of malignancy.
Wen YH; Yee H; Goswami S; Shukla PS
Int J Gynecol Pathol; 2009 Mar; 28(2):187-92. PubMed ID: 19188814
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome.
Brustmann H
Int J Gynecol Pathol; 2008 Jul; 27(3):380-9. PubMed ID: 18580315
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study.
Brustmann H
Gynecol Oncol; 2005 Sep; 98(3):396-402. PubMed ID: 16005054
[TBL] [Abstract][Full Text] [Related]
17. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum?
Jordan SJ; Green AC; Whiteman DC; Webb PM;
Gynecol Oncol; 2007 Nov; 107(2):223-30. PubMed ID: 17662378
[TBL] [Abstract][Full Text] [Related]
19. [Expression of glucose transporter-1 in endometrial hyperplasia and well-differentiated endometrioid adenocarcinoma].
Liu AJ; Hou N; Chen LZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Aug; 23(4):398-400. PubMed ID: 12940086
[TBL] [Abstract][Full Text] [Related]
20. The utility of calretinin, inhibin, and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors.
Cathro HP; Stoler MH
Hum Pathol; 2005 Feb; 36(2):195-201. PubMed ID: 15754297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
